Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 15/20 | 0.68 |
| ▸ | FEN1 | P39748 | 15/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15917674 | 0.82 | FEN1 (1.00) | ALOX5APFEN1 | |
| SCHEMBL29685241 | 0.81 | ALDH1A1 (0.53) | ALOX5APFEN1HSP90AA1METAP2HSP90AB1 | |
| SCHEMBL29739505 | 0.79 | HSP90AA1 (0.50) | ALOX5APFEN1HSP90AA1METAP2HSP90AB1 | |
| SCHEMBL14988502 | 0.79 | HSP90AA1 (0.50) | ALOX5APFEN1HSP90AA1METAP2HSP90AB1 | |
| SCHEMBL5550517 | 0.79 | ALOX5AP (0.53) | ALOX5APFEN1 | |
| SCHEMBL6075271 | 0.79 | ALOX5AP (0.53) | ALOX5APFEN1 | |
| SCHEMBL27990067 | 0.78 | HSP90AA1 (0.53) | ALOX5APFEN1HSP90AA1METAP2HSP90AB1 | |
| SCHEMBL15915519 | 0.78 | ALOX5AP (0.56) | ALOX5APFEN1 | |
| SCHEMBL8259696 | 0.78 | FEN1 (0.52) | ALOX5APFEN1 | |
| SCHEMBL28107573 | 0.77 | FEN1 (0.66) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100457757-C | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2009-02-04 | — | — | CN | disclosed |
| EP-1572670-B1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-7132425-B2 | 5-substituted-six-membered heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1572670-A1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| CN-1640877-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2005-07-20 | — | — | CN | disclosed |
| CN-1202108-C | Spiro compounds, processes and intermediates | BANYU PHARMA CO LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | CHEN SHAOQING (US) | 2004-07-29 | — | — | US | disclosed |
| WO-2004052869-A1 | 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
| CN-1370168-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2002-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | GCK, GCKR, GALK1 | ALOX5AP 3219/4885FEN1 4364/4885HSP90AA1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.